This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.
Registration ID: 637632
Submitted by lobbyist on: May 1, 2017 01:13:58 PM
Accepted by Registrar on: May 2, 2017 10:08:07 AM
Designated Filer Information
| Keon, James J |
| 4120 Yonge Street Suite 409 | |
|
Toronto, ON, M2P 2B8
|
416-223-2333 |
| Canada |
Organization Information
| Canadian Generic Pharmaceutical Association (CGPA) |
| The CGPA's mission is to promote an environment which supports and enhances the provision of affordable generic medications to Canadians and patients around the world. The Association researches and develops positions regarding a wide variety of policies, regulations and legislation that affects our member companies. We promote our sector's interests by publishing material as well as directly contacting government officials, the media and other opinion leaders and decision makers. |
| 4120 Yonge Street Suite 409 | |
|
Toronto, ON, M2P 2B8
|
416-223-2333 |
| Canada |
Relevant Affiliates
Government or Government Agency Funding
Other Controlling or Directing Interests
Active Registration Period
| May 1, 2017 | |
| October 28, 2017 |
Organization's In-House Lobbyists
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Aligning BC's policies regarding reimbursement of generic products with agreement being negotiated with Council of the Federation. Developing a regulatory pathway for biosimilars. Addressing use of brand coupon cards. Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Minister | Dix, Adrian | Minister of Health | July 24, 2017 |
| Public Agency | Health | May 1, 2017 |
International Trade
Development, establishment, amendment or termination of any program, policy or decision
Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | International Trade | May 1, 2017 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
International Trade
Development, establishment, amendment or termination of any program, policy or decision
Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | International Trade | May 1, 2017 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Aligning BC's policies regarding reimbursement of generic products with agreement being negotiated with Council of the Federation. Developing a regulatory pathway for biosimilars. Addressing use of brand coupon cards.Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Minister | Dix, Adrian | Minister of Health | July 24, 2017 |
| Public Agency | Health | May 1, 2017 |
International Trade
Development, establishment, amendment or termination of any program, policy or decision
Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | International Trade | May 1, 2017 |